Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease

Annals of the American Thoracic Society

Volumn 11, Issue 3, 2014, Pages 316-325

  Leidy, Nancy K ^a   Murray, Lindsey T ^a   Jones, Paul ^b   Sethi, Sanjay ^c  

^a EVIDERA   (United States)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Chronic obstructive pulmonary disease; Clinical trials; Exacerbations; Outcome measures; Patient reported outcomes

Indexed keywords

AZD 9668; BUDESONIDE PLUS FORMOTEROL; LEVOFLOXACIN; TIOTROPIUM BROMIDE; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; N-((5-(METHANESULFONYL)PYRIDIN-2-YL)METHYL)-6-METHYL-5-(1-METHYL-1H-PYRAZOL-5-YL)-2-OXO-1-(3-(TRIFLUOROMETHYL)PHENYL)-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE; PYRIDONE DERIVATIVE; SULFONE;

ARTICLE; BREATHLESSNESS COUGH AND SPUTUM SCALE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CRONBACH ALPHA COEFFICIENT; DISEASE EXACERBATION; EXACERBATION OF CHRONIC PULMONARY DISEASE TOOL; HIGH RISK PATIENT; HUMAN; INTERNAL CONSISTENCY; MAINTENANCE THERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; REPRODUCIBILITY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOM; UNITED STATES; VALIDITY; AGED; COHORT ANALYSIS; COMPLICATION; CONTROLLED STUDY; FEMALE; MALE; MEDICAL RECORD; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME;

AGED; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; COHORT STUDIES; FEMALE; HUMANS; LEVOFLOXACIN; MALE; MEDICAL RECORDS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRIDONES; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SULFONES; TIME FACTORS;

EID: 84898713016     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201309-305OC     Document Type: Article

References (49)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. 2011 [accessed 2013 Aug]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD- Report-2011-Feb21.pdf.
2. National Heart Lung and Blood Institute. Morbidity and mortality chartbook on cardiovascular, lung and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 2009 [accessed 2013 Aug]. Available from: http://www.nhlbi.nih.gov/resources/docs/2009-ChartBook.pdf
3. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852. (Pubitemid 35178607)
4. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121:121S-126S. (Pubitemid 34497328)
5. Ries AL. Impact of chronic obstructive pulmonary disease on quality of life: the role of dyspnea. Am J Med 2006;119:12-20. (Pubitemid 44402280)
6. Spencer S, Calverley PM, Sherwood Burge P, Jones PW; ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-128. (Pubitemid 32095261)
7. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim Care Respir J 2011;20:257-268.
8. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-773. (Pubitemid 47321908)
9. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
10. Brusse-Keizer M, van der Palen J, van der Valk P, Hendrix R, Kerstjens H. Clinical predictors of exacerbation frequency in chronic obstructive pulmonary disease. Clin Respir J 2011;5:227-234.
11. Tashkin DP. Frequent exacerbations of chronic obstructive pulmonary disease - a distinct phenotype? N Engl J Med 2010;363:1183-1184.
12. Calverley P, Pauwels Dagger R, Lo̊fdahl CG, Svensson K, Higenbottam T, Carlsson LG, Ståhl E. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J 2005;26:406-413. (Pubitemid 41264201)
13. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:398S-401S. (Pubitemid 30314474)
14. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008;177:396-401. (Pubitemid 351317582)
15. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
16. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Wang C, Bourbeau J. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J 2010;35:1022-1030.
17. Anthonisen NR, Manfreda J, Warren CP, Hersh field ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204. (Pubitemid 17009877)
18. Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax 2012;67:238-243.
19. Quint JK, Donaldson GC, Hurst JR, Goldring JJ, Seemungal TR, Wedzicha JA. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J 2011;37:501-507.
20. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Efficacy Working Party (EWP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. EMEA/CHMP/EWP/139391/2004. 2005 Jul [accessed 2013 Aug]. Available from: http://www.emea.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003637.pdf.
21. Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2009;74:65132-65133.
22. Food and Drug Administration. Draft guidance for industry on chronic obstructive pulmonary disease: developing drugs for treatment. Fed Regist 2007;72:63618.
23. Food and Drug Administration. Guidance for industry on acute bacterial exacerbations of chronic bronchitis in patients with chronic obstructive pulmonary disease: developing antimicrobial drugs for treatment. Fed Regist 2012;77:2012-24035.
24. Jones PW, Chen WH, Wilcox TK, Sethi S, Leidy NK; EXACT-PRO Study Group. Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest 2011;139:1388-1394.
25. Leidy NK, Murray LT. Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD 2013;10:393-398.
26. Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K, Petrillo J, Powers J, Sethi S; EXACT-PRO Study Group. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 2010;13:965-975.
27. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S; EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011;183:323-329.
28. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity - establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1 - eliciting concepts for a new PRO instrument. Value Health 2011;14:967-977.
29. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity - establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2 - assessing respondent understanding. Value Health 2011;14:978-988.
30. Vogelmeier C, Aquino TO, O'Brien CD, Perrett J, Gunawardena KA. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD 2012;9:111-120.
31. Kuna P, Jenkins M, O 'Brien CD, Fahy WA. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med 2012;106:531-539.
32. Leidy NK, Rennard SI, Schmier J, Jones MK, Goldman M. The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation. Chest 2003;124:2182-2191. (Pubitemid 38010588)
33. Leidy NK, Schmier JK, Jones MK, Lloyd J, Rocchiccioli K. Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. Respir Med 2003;97:S59-70. (Pubitemid 36124432)
34. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-1327.
35. Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire. Chest 2007;132:456-463. (Pubitemid 47282376)
36. Bourbeau J, Ford G, Zackon H, Pinsky N, Lee J, Ruberto G. Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J 2007;30:907-913. (Pubitemid 351194794)
37. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, et al.; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-162.
38. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, Deng JM, MacNee W, Zhong XN. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010;80:445-452.
39. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J 2006;15:346-353. (Pubitemid 44810150)
40. Ehsan M, Khan R, Wakefield D, Qureshi A, Murray L, Zuwallack R, Leidy NK. A longitudinal study evaluating the effect of exacerbations on physical activity in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013;10:559-564.
41. Halpin DM, Laing-Morton T, Spedding S, Levy ML, Coyle P, Lewis J, Newbold P, Marno P. A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Prim Care Respir J 2011;20:324-331, 2 p following 331.
42. Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M. Patient's perception of exacerbations of COPD - the PERCEIVE study. Respir Med 2007;101:453-460. (Pubitemid 46196335)
43. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-1613. (Pubitemid 30329036)
44. Adams R, Chavannes N, Jones K, Ostergaard MS, Price D. Exacerbations of chronic obstructive pulmonary disease - a patients' perspective. Prim Care Respir J 2006;15:102-109.
45. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010;19:113-118.
46. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis 2009;4:245-251.
47. Haughney J, Partridge MR, Vogelmeier C, Larsson T, Kessler R, Ståhl E, Brice R, Löfdahl CG. Exacerbations of COPD: quantifying the patient's perspective using discrete choice modelling. Eur Respir J 2005;26:623-629. (Pubitemid 41448659)
48. Kessler R, Ståhl E, Vogelmeier C, Haughney J, Trudeau E, Lo̊fdahl CG, Partridge MR. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006;130:133-142. (Pubitemid 44116851)
49. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R; IMPAC Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004;59:387-395. (Pubitemid 38624744)